)
Thomas Schirrmann
CEO & Co-Founder,
YUMAB
Thomas Schirrmann is biochemist by training and holds an PhD in immunology. He worked for 25 years in applied research with focus on recombinant antibody technologies and immunotherapies including CAR-NK, bispecifics and antibody fusion proteins. He published >80 scientific publications and is inventor of several patents. He founded and led biotech companies such as YUMAB GmbH (2012, CEO), CORAT Therapeutics GmbH (2020, founding CEO & COO) and Valerius BioPharma GmbH.
Sessions